Equity Overview
Price & Market Data
Price: $2.97
Daily Change: -$0.21 / 7.07%
Daily Range: $2.85 - $3.27
Market Cap: $36,420,882
Daily Volume: 329,098
Performance Metrics
1 Week: -16.85%
1 Month: 19.35%
3 Months: 51.02%
6 Months: 76.19%
1 Year: -50.25%
YTD: -13.95%
Company Details
Employees: 42
Sector: Health technology
Industry: Biotechnology
Country:
Details
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.